LifeWatch AG

EQS-Adhoc: LifeWatch AG: LifeWatch AG und BioTelemetry, Inc. erhalten kartellrechtliche Freigabe

EQS Group-Ad-hoc: LifeWatch AG / Schlagwort(e): Übernahmeangebot
LifeWatch AG: LifeWatch AG und BioTelemetry, Inc. erhalten kartellrechtliche

08.05.2017 / 15:22 CET/CEST
Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR
LifeWatch AG und BioTelemetry, Inc. erhalten kartellrechtliche Freigabe

Zug/Schweiz und Malvern, PA - 8. Mai 2017 - LifeWatch AG (SIX Swiss
Exchange:LIFE) und BioTelemetry, Inc. (NASDAQ:BEAT) geben, wirksam per 5. Mai
2017, die vorzeitige Beendigung der geltenden Wartezeit unter dem
Hart-Scott-Rodino Antitrust Improvements Act von 1976 ("HSR") in Hinsicht auf
das zuvor angekündigte Übernahmeangebot von BioTelemetry für alle ausstehenden
Aktien der LifeWatch AG bekannt. Diese Bewilligung untersteht keinen Bedingungen
oder Forderungen, weder für LifeWatch noch für BioTelemetry oder eine ihrer
Tochtergesellschaften. LifeWatch und BioTelemetry erhielten ausserdem alle
notwendigen kartellrechtlichen Bewilligungen von der Mazedonischen Kommission
(Macedonian Commission), welche aufgrund der Aktivitäten von LifeWatch
Mazedonien, eine hundertprozentige Tochtergesellschaft der LifeWatch AG,
notwendig waren.

Mit dem Ablauf der HSR-Wartefrist wird eine der Konditionen des ausstehenden
Übernahmeangebots, welches - wie im Angebotsprospekt von BioTelemetry per 24.
April 2017 beschrieben - nach wie vor von anderen Konditionen abhängt, erfüllt.
Vorbehaltlich der Erfüllung der anderen Konditionen erwartet BioTelemetry den
Abschluss der Übernahme im dritten Quartal 2017.

Gemäss aktuellem Zeitplan beginnt die Hauptangebotsfrist am 10. Mai 2017 und
endet voraussichtlich am 23. Mai 2017, unter Vorbehalt einer Verlängerung der

Für Rückfragen:
LifeWatch AG, Andrew Moore, CFO
c/o Communicators AG , Ralph Spillmann
Mobile: +41 79 514 64 84

Zu LifeWatch AG
LifeWatch AG, mit Hauptsitz in Zug und Kotierung an der SIX Swiss Exchange
(LIFE) in der Schweiz, ist ein führender Anbieter von ferngesteuerten
diagnostischen "Digital Health" Dienstleistungen. Die Dienstleistungen von
LifeWatch liefern den Ärzten wichtige Informationen zur angemessenen Behandlung
ihrer Patienten mit dem Ziel, die Behandlung zu optimieren. LifeWatch AG verfügt
über operative Tochtergesellschaften in den USA, der Schweiz, Israel und der
Türkei und ist die Muttergesellschaft von LifeWatch Services, Inc., LifeWatch
Technologies Ltd. und LifeWatch Turkey Holding AG (Joint Venture). LifeWatch
Services, Inc. ist ein führender US-Anbieter für
Herzüberwachungsdienstleistungen. LifeWatch Technologies Ltd. in Israel ist ein
führender Hersteller von Digital-Health-Produkten. LifeWatch Sağlık Hizmetlerine
A.S. ist die operative Tochtergesellschaft der LifeWatch Turkey Holding AG und
Anbieter von Herzüberwachungsdienstleistungen in der Türkei.

Für weitere Informationen:

E-Mail Alert:Um regelmässig die neusten Informationen zu LifeWatch zu erhalten
und Unterlagen anzufordern, registrieren Sie sich bitte

Zu BioTelemetry
BioTelemetry, Inc., früher als CardioNet bekannt, ist ein führendes Unternehmen
im Bereich kabelloser Medizinaltechnologie. Der Fokus liegt auf der
Bereitstellung von Gesundheitsdaten zur Verbesserung der Lebensqualität sowie
zur Reduktion der Gesundheitskosten. Das Unternehmen bietet zurzeit
Herzüberwachungs-Dienstleistungen an und produziert Geräte mit einem primären
Fokus auf die Herzüberwachung sowie zentralisierte Dienstleistungen für

Für weitere Informationen:

Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements regarding, among other
things, statements about BioTelemetry's proposed acquisition of LifeWatch AG,
including the timing and success of the tender offer. These statements may be
identified by words such as "expect," "anticipate," "estimate," "intend,"
"plan," "believe," "promises", "projects," and other words and terms of similar
meaning. Such forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including important factors that could
delay, divert, or change any of these expectations, and could cause actual
outcomes and results to differ materially from current expectations. Factors
that may materially affect such forward-looking statements include:
BioTelemetry's ability to successfully complete the tender offer for LifeWatch's
shares and the failure of any of the conditions to BioTelemetry's tender offer
to be satisfied. For further details and a discussion of these and other risks
and uncertainties, please see BioTelemetry's public filings with the Securities
and Exchange Commission, including the company's latest periodic reports on Form
10-K and 10-Q respectively, LifeWatch's past press releases, reports and other
information posted on LifeWatch's website. Readers are cautioned not to put
undue reliance on forward-looking statements, which reflect only opinions as of
the date of this press release. BioTelemetry and LifeWatch do not undertake, and
specifically disclaim, any obligation to publicly update or amend any
forward-looking statement, whether as a result of new information, future
events, or otherwise.

The public tender offer described in the offer documents (the "Offer") is not
being and will not be made, directly or indirectly, in any country or
jurisdiction in which it would be considered unlawful or otherwise violate any
applicable laws or regulations, or which would require BioTelemetry or any of
its subsidiaries to change or amend the terms or conditions of the Offer in any
material way, to make an additional filing with any governmental, regulatory or
other authority or take additional action in relation to the Offer. It is not
intended to extend the Offer to any such country or jurisdiction. Any such
documents relating to the Offer must neither be distributed in any such country
or jurisdiction nor be sent into such country or jurisdiction, and must not be
used for the purpose of soliciting the purchase of securities of LifeWatch by
any person or entity resident or incorporated in any such country or

Notice to U.S. Persons Holding LifeWatch Shares
The Offer is made for the securities of a non-U.S. company. The Offer is subject
to the disclosure and procedural requirements of Switzerland, which are
different from those of the United States (the "U.S.").

The Offer may not be accepted before expiration of a cooling-off period of ten
(10) trading days, which will run from April 25, 2017 through May 9, 2017,
unless extended by the Swiss Takeover Board.

According to the laws of Switzerland, LifeWatch shares tendered into the Offer
may be withdrawn after they are tendered until the expiration of the main offer

BioTelemetry and any of its subsidiaries and any advisor, broker or financial
institution acting as an agent or for the account or benefit of BioTelemetry or
the Offeror may, subject to applicable Swiss securities laws, rules and
regulations, make certain purchases of, or arrangements to purchase, LifeWatch
shares from shareholders of LifeWatch who are willing to sell their LifeWatch
shares outside the Offer from time to time, including purchases in the open
market at prevailing prices or in private transactions at negotiated prices. The
Offeror will disclose promptly any information regarding such purchases of
LifeWatch shares in Switzerland through the electronic media and/or the stock
exchange and in the U.S. by means of a press release, if and to the extent
required under applicable laws, rules and regulations in Switzerland.

It may be difficult for U.S. holders to enforce their rights and any claim
arising out of U.S. federal securities laws, since LifeWatch is located in a
non-U.S. jurisdiction, and some or all of its officers and directors may be
residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a
non-U.S. company or its officers or directors in a non-U.S. court for violations
of the U.S. securities laws. Further, it may be difficult to compel a non-U.S.
company and its affiliates to subject themselves to a U.S. court's judgment.

The receipt of cash and stock consideration in the Offer by a U.S. shareholder
will generally be a taxable transaction for U.S. federal, state and local income
tax purposes. Each U.S. shareholder is urged to consult his independent
professional adviser immediately regarding the tax consequences of acceptance of
the Offer.

Securities may not be offered or sold in the U.S. absent registration or an
exemption from registration under the U.S. Securities Act. It is expected that
the Offer will be subject to a Tier I exemption pursuant to Rule 14d-1(c) of the
U.S. Securities Exchange Act of 1934, as amended, and that the issuance of
BioTelemetry Common Stock in connection therewith will be exempt from
registration under the U.S. Securities Act of 1933, as amended, pursuant to Rule
802 thereof.

Neither the Securities and Exchange Commission nor any securities commission of
any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed
upon the merits or fairness of the Offer, or (c) passed upon the adequacy or
accuracy of the disclosure in the pre-announcement. Any representation to the
contrary is a criminal offense in the U.S.

Im Zweifelsfall gilt die englische Originalmeldung.

Zusatzmaterial zur Meldung:

Dokumenttitel: 20170508_Antitrust Clearance_DE
Ende der Ad-hoc-Mitteilung------------------------------------------------------

Sprache:       Deutsch

Unternehmen:   LifeWatch AG

               Baarerstrasse 139

               6300 Zug


Telefon:       +41 41 728 67 78


ISIN:          CH0012815459

Valorennummer: 811189

Börsen:        Freiverkehr in Berlin, Stuttgart; Open Market in Frankfurt; SIX
Swiss Exchange


Ende der Mitteilung EQS Group News-Service


571029  08.05.2017 CET/CEST

Weitere Meldungen: LifeWatch AG

Das könnte Sie auch interessieren: